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Human Factor Va1 and Factor Va2: Properties in the Procoagulant and
Anticoagulant Pathways†
Lico Hoekema, Gerry A. F. Nicolaes, H. Coenraad Hemker, Guido Tans, and Jan Rosing*
CardioVascular Research Institute Maastricht, Maastricht UniVersity, Maastricht, The Netherlands
ReceiVed September 16, 1996; ReVised Manuscript ReceiVed December 31, 1996X
ABSTRACT: Human plasma factor V is heterogeneous and yields two forms of activated factor V that bind
with low (factor Va1) and high affinity (factor Va2) to phospholipids. The properties of factor Va1 and
factor Va2 in the anticoagulant and procoagulant pathways were evaluated by comparing their sensitivity
for inactivation by APC and their ability to act as cofactor in prothrombin activation. At low phospholipid
concentrations and on membranes containing low amounts of phosphatidylserine (PS), factor Va1 was
inactivated by APC at 15-fold lower rates than factor Va2, both in the absence and in the presence of
protein S. At high phospholipid concentrations and on membranes with more than 15 mol % PS, factor
Va1 and factor Va2 were inactivated with equal efficiency. Differences between cofactor activities of
factor Va1 and factor Va2 in prothrombin activation were only observed on membranes with less than 7.5
mol % PS. Due to the different phospholipid requirements of APC-catalyzed factor Va inactivation and
of expression of factor Va cofactor activity in prothrombin activation, the thrombin-forming capacity of
factor V1 was 7-fold higher than that of factor V2 in a reaction system containing factor Xa, prothrombin,
APC, protein S, vesicles with a phospholipid composition resembling that of activated platelets, and traces
of thrombin to initiate prothrombin activation. This shows that in the process of generation, expression,
and down-regulation of factor Va cofactor activity on physiological membranes, the overall procoagulant
activity of factor V1 can considerably exceed that of factor V2.
Inactivation of factor Va by activated protein C (APC)1
plays an important role in the down-regulation of thrombin
formation (Esmon, 1989). Factor Va loses its cofactor
activity in prothrombin activation after APC-catalyzed cleav-
age in its heavy-chain domain at positions Arg506and Arg306
(Kalafatiset al., 1994, 1995; Nicolaeset al., 1995). Factor
Va inactivation by APC is stimulated by negatively charged
phospholipids (Walkeret al., 1979; Bakkeret al., 1992) and
protein S (Bakkeret al., 1992; Walker, 1980; Solymosset
al., 1988). Recently, we reported that protein S promotes
factor Va inactivation by specifically accelerating the slow
peptide bond cleavage at Arg306 (Rosinget al., 1995).
The physiological importance of APC and protein S is
demonstrated by the association of venous thrombosis with
hereditary deficiencies in protein C (Griffinet al., 1981) or
protein S (Schwarzet al., 1984; Compet al., 1984) and by
the occurrence of familial thrombophilia in individuals that
have a hereditary defect (replacement of Arg506 by Gln) that
makes factor Va insensitive to proteolytic inactivation by
APC (APC resistance, Dahlba¨ck et al., 1993; Bertinaet al.,
1994).
In 1993 we reported (Rosinget al., 1993) that plasma
contains two forms of factor V which likely differ in the
degree of glycosylation in the carboxy-terminal C2 domain
(Ortel et al., 1994a). Activation by thrombin yields two
forms of factor Va (factor Va1 and factor Va2) with different
affinities for procoagulant membrane surfaces and which
exhibit different cofactor activities in prothrombin activation.
Considering the physiological importance of down-regulation
of factor Va activity via the anticoagulant pathway, we have
compared the procoagulant and anticoagulant properties of
factors Va1 and Va2 in order to get insight in their
contributions toin ViVo thrombin formation. We report that
under several conditions factors Va1 nd Va2 have similar
procoagulant activity whereas they considerably differ in their
sensitivity for APC. In these situations, the overall proco-
agulant activity of factor V1 is higher than that of factor V2.
EXPERIMENTAL PROCEDURES
Materials. Phospholipids were obtained from Avanti Polar
Lipids, Pelham, AL. Small unilamellar phospholipid vesicles
were prepared as described before (Rosinget al., 1993).
S2238, S2366, and I2581 were supplied by Chromogenix,
Mölndal, Sweden. Materials used for protein purification
were purchased from Pharmacia. Human prothrombin,
thrombin, and factor Xa were prepared by earlier described
procedures (DiScipioet al., 1977; Pletcher & Nelsestuen,
1982; Bocket al., 1989). Human protein C was prepared
and activated as reported by Gruberet al. (1989). Human
protein S was obtained from Enzyme Research Laboratories
Inc. (Swansea, U.K.). Human factor V1, factor V2, factor
Va1, and factor Va2 were purified as described previously
(Rosinget al., 1993).
Protein Concentrations.Molar prothrombin, thrombin,
and factor Xa concentrations were determined as described
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before (Chase & Shaw, 1969; Smith, 1973). APC concen-
trations were determined with S2366 using kinetic parameters
reported by Salaet al.(1984). Protein S concentrations were
calculated from theA280 using anA2801% of 9.5 andMr )
70 000 for protein S (DiScipio & Davie, 1979). Factor Va
was quantitated as described below.
Factor Va Assay.Cofactor activity of factor Va was
quantitated by determining the rate of factor Xa-catalyzed
prothrombin activation in reaction mixtures that contained
a limiting amount of factor Va, 5 nM factor Xa, 50µM
phospholipid vesicles (DOPS/DOPC, 10/90, mol/mol), and
0.5 µM prothrombin (Tanset al., 1991a). Rates of pro-
thrombin activation were determined with S2238 (Rosing
et al., 1980). The molar factor Va concentration in the assay
mixture was calculated from the rate of prothrombin activa-
tion using a turnover number of 6000 mol of prothrombin
activated per minute per mole of factor Xa-Va complex
(Tanset al., 1991b).
InactiVation of Factor Va by APC.Factor Va1 or factor
Va2 was incubated at 37°C with phospholipid vesicles in
the absence or presence of protein S in a reaction mixture
containing 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM
CaCl2, and 5 mg/mL BSA, and its concentration was
determined in triplicate to obtain [factor Va]t)0. Factor Va
inactivation was started by addition of APC, and the time-
dependent loss of factor Va cofactor activity was followed
as described in the previous paragraph.
CurVe Fitting of Pseudo-First Order Time Courses of
Factor Va InactiVation. Time courses of factor Va1 or factor
Va2 inactivation by APC were determined by monitoring the
loss of cofactor activity of factor Va as a function of time.
Data reported in the literature (Kalafatiset al., 1994, 1995;
Nicolaeset al., 1995; Rosinget al., 1995) demonstrate that
the loss of factor Va cofactor activity can proceed via two
pathways:
in which factor Vaint is a reaction intermediate with partial
cofactor activity, factor Vai is a form of factor Va that has
completely lost its cofactor activity,k506 is the second-order
rate constant for cleavage at Arg506, k306 is the second-order
rate constant for cleavage at Arg306 in factor Vaint, andk′306
is the second-order rate constant for cleavage at Arg306 in
native factor Va. The rate constantsk506, k306, andk′306 and
the cofactor activity of factor Vaint were obtained by fitting
time courses of factor Va inactivation to eq 3 using nonlinear
least-squares regression analysis (Nicolaeset al., 1995;
Rosinget al., 1995).
In this equation,k306, k′306, andk506 are the rate constants
for peptide bond cleavages defined above andB represents
the residual cofactor activity (percent of native factor Va)
of the reaction intermediate factor Vaint.
Cofactor ActiVity of Factor Va in Prothrombin ActiVation.
Factor Va1 or factor Va2 was incubated with 2.5 pM factor
Xa and phospholipid vesicles at 37°C in 25 mM Hepes (pH
7.5), 175 mM NaCl, 3 mM CaCl2, and 5 mg/mL BSA. After
5 min, prothrombin was added, and 2 and 4 min later, the
amount of thrombin formed was quantitated as described
before (Rosinget al., 1980).
RESULTS
Effect of Phospholipid on InactiVation of Factor Va1 and
Factor Va2 by APC in the Absence and Presence of Protein
S. Recently, we have shown (Nicolaest al., 1995) that
inactivation of factor Va by APC proceeds via a biphasic
reaction (cf. Figure 1) in which fast cleavage at Arg506 in
the heavy chain of factor Va results in the formation of an
intermediate with partial cofactor activity in prothrombin
activation that is fully inactivated by APC after slow cleavage
at Arg306. We subsequently reported that protein S promotes
factor Va inactivation by specifically accelerating cleavage
at Arg306 (Rosinget al., 1995).
It was also reported (Rosinget al., 1993) that plasma factor
V is heterogeneous and yields two forms of factor Va (Va1
and Va2) after activation that bind with different affinities
to negatively charged membranes.
FIGURE 1: Inactivation of factor Va1 and factor Va2 by APC. 1.5
nM purified human factor Va1 (9,0) or factor Va2 (b,O) was
incubated at 37°C with 1 nM APC (A, B) or 0.12 nM APC (C)
without (9,b) or with (0,O) 200 nM protein S in 25 mM Hepes
(pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5 mg/mL BSA, and (A,B)
5 µM PS/PC (5/95, mol/mol) or (C) 50µM DOPS/DOPC (20/80,
mol/mol). At the indicated time points, factor Va activity was
determined as described under Experimental Procedures. The solid
lines represent a best fit of the data to eq 3 given under Experimental
Procedures using nonlinear least-squares regression analysis.
factor Va98
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factor Vaint98
k306
factor Vai (1)
factor Va98
k′306
Vai (2)
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3332 Biochemistry, Vol. 36, No. 11, 1997 Hoekema et al.
In Figure 1, it is shown that on membranes with 5 mol %
phosphatidylserine, factor Va1 was inactivated by APC at
considerably lower rates than factor Va2, both in the absence
(Figure 1A) and in the presence of protein S (Figure 1B).
The rate constants for APC-catalyzed cleavage at Arg506and
Arg306 (k506 andk306) were about 15 times lower for factor
Va1 than for factor Va2 (Table 1). When the same experi-
ment was performed in the presence of a 10-fold higher
concentration of phospholipid vesicles containing 20 mol %
phosphatidylserine, inactivation was much faster, and factor
Va1 and factor Va2 were inactivated by APC at the same
rate, both in the absence and in the presence of protein S
(Figure 1C).
APC-Catalyzed InactiVation of Factor Va1 and Factor Va2
on Membranes Containing Varying Amounts of Phosphati-
dylserine. Time courses of factor Va1 and factor Va2
inactivation by APC (cf. Figure 1) were determined on 5
µM phospholipid vesicles containing varying amounts of
phosphatidylserine. Since protein S had similar effects on
the inactivation of both forms of factor Va, we have
performed these experiments in the absence of protein S.
The time courses of factor Va inactivation were fitted using
an equation for a biphasic inactivation reaction [eq 3;cf.
Nicolaeset al.(1995) and Rosinget al.(1995)] which yielded
the rate constants,k506 andk306, for APC-catalyzed cleavage
at Arg506 and Arg306 in the heavy chain of factor Va.
Increasing the amount of phosphatidylserine in the membrane
surface resulted in an increase of bothk506 (Figure 2A) and
k306 (Figure 2B) for each form of factor Va. This indicates
that the two cleavages required for full inactivation of factor
Va are equally affected by variation of the phosphatidylserine
content of the membrane. The data further show that factor
Va1 was inactivated at considerably lower rates than factor
Va2 on membranes with less than 15 mol % phosphati-
dylserine. At a higher phosphatidylserine content, both forms
of factor Va were inactivated with similar rates, and at 30
mol % phosphatidylserine, factor Va1 was even activated
about 2 times faster than factor Va2.
Effect of Variation of the Phospholipid Concentration on
APC-Catalyzed InactiVation of Factor Va1 and Factor Va2.
The previous experiments have shown that factor Va1 w s
inactivated by APC at considerably lower rates than factor
Va2 on 5 µM phospholipid vesicles containing 5 mol %
phosphatidylserine. Since this likely reflects differences in
the binding affinities of factors Va1 and Va2 for membrane
surfaces (Rosinget al., 1993), it is expected that the
difference in sensitivity of both forms of factor Va for APC
will annihilate at higher phospholipid concentrations. The
experiment presented in Figure 3 shows that this indeed
occurs. At low phospholipid concentrations, the rate con-
stants,k506 (Figure 3A) andk306 (Figure 3B), for factor Va1
inactivation were∼15-fold lower than those for factor Va2.
At increasing phospholipid concentrations, the rates of factor
Va inactivation gradually converged, and at 200µM phos-
pholipid, the difference between the rates of factor Va1 and
Va2 inactivation was about 2-fold.
Effect of Phospholipid Composition and Concentration on
the Cofactor ActiVity of Factor Va1 and Factor Va2 in
Prothrombin ActiVation. In a previous paper (Rosinget al.,
1993), we reported that at low concentrations of phospholipid
vesicles with a low phosphatidylserine content factor Va2
exhibits a higher cofactor activity in prothrombin activation
than factor Va1. In Figure 4, it is shown, however, that
optimal expression of factor Va cofactor activity in pro-
thrombin activation required much less phospholipid and
phosphatidylserine than APC-catalyzed factor Va inactivation
(cf. Figures 2 and 3). Although at low phospholipid
concentrations and on membranes with a low phosphati-
dylserine content factor Va2 was a more effective cofactor
than factor Va1, the cofactor activities of both forms of factor
Va were optimal and similar at 5µM phospholipid vesicles
containing 10 mol % phosphatidylserine (Figure 4A) and
Table 1: Rate Constants (M-1 s-1) for APC-Catalyzed Peptide
Bond Cleavages in Factor Va1 nd Factor Va2a
no protein S with protein S
k506 k306 k506 k306
5 µM PS/PC (5/95)
factor Va1 8.3× 105 3.4× 104 1.1× 106 5.7× 105
factor Va2 7.0× 106 5.1× 105 1.6× 107 3.3× 106
50µM PS/PC (20/80)
Factor Va1 2.1× 108 6.4× 106 2.2× 108 1.2× 108
Factor Va2 1.2× 108 6.6× 106 1.2× 108 1.4× 108
a The rate constants of APC-catalyzed inactivation of factor Va were
obtained by fitting the time courses of factor Va inactivation (Figure
1) using the equation for a biphasic inactivation reaction described under
Experimental Procedures.
FIGURE 2: Effect of phosphatidylserine on rate constants of APC-
catalyzed cleavage at Arg506 and Arg306 in factor Va1 and factor
Va2. 1.5 nM purified human factor Va1 (9) or factor Va2 (b) was
incubated at 37°C with varying amounts (0.4-60 nM) of APC in
25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5 mg/mL
BSA, and 5µM DOPS/DOPC vesicles with the mole percentage
phosphatidylserine (DOPS) indicated in the figure. Rate constants
for APC-catalyzed cleavage at Arg506 (k506) and Arg306 (k306) were
obtained from the best fit of the time courses of factor Va
inactivation (cf. Figure 1) to eq 3 given under Experimental
Procedures using nonlinear least-squares regression analysis. Plotted
are k506 (A) and k306 (B) as a function of the phosphatidylserine
content of the membrane.
FIGURE3: Effect of the phospholipid concentration on rate constants
of APC-catalyzed cleavage at Arg506 and Arg306 in factor Va1 and
factor Va2. 1.5 nM purified human factor Va1 (9) or factor Va2
(b) was incubated at 37°C with varying amounts (2.6-46 nM) of
APC in 25 mM Hepes (pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5
mg/mL BSA, and varying amounts of DOPS/DOPC (5/95, mol/
mol). Rate constants for APC-catalyzed cleavage at Arg506 (k506)
and Arg306 (k306) were obtained from the best fit of the time courses
of factor Va inactivation (cf. Figure 1) to eq 3 given under
Experimental Procedures using nonlinear least-squares regression
analysis. Plotted arek506 (A) and k306 (B) as a function of the
phospholipid concentration.
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on 50µM phospholipid vesicles with 5 mol % phosphati-
dylserine (Figure 4B).
Comparison of the Procoagulant ActiVi ies of Factor V1
and Factor V2. The experiments presented in the previous
paragraphs show that under several conditions (e.g., 20µM
phospholipid vesicles containing 10 mol % phosphati-
dylserine) the cofactor activities of factor Va1 nd factor Va2
in prothrombin activation were approximately similar (Figure
4) while their sensitivities for APC were considerably
different (Figures 2 and 3). This means that in a system, in
which factor V is activated by factor Xa/thrombin and in
which the factor Va that is formed is allowed to express its
cofactor activity in prothrombin activation in the presence
of APC and protein S, factor V1 will exhibit a higher overall
procoagulant activity (i.e., will yield more thrombin) than
factor V2. This was confirmed by the experiment presented
in Figure 5. In this experiment, equal amounts of factor V1
or factor V2 were activated by factor Xa and thrombin in
reaction mixtures containing 12.5µM vesicles with a
phospholipid composition identical to that of activated
platelet membranes (Beverset al., 1983), 1µM prothrombin,
4 pM factor Xa , 2 nM APC, and 200 nM protein S at
physiological ionic strength. In the case of factor V1, this
indeed resulted in the formation of much more thrombin than
in the case of factor V2 (Figure 5). From the fact that the
final level of thrombin formed with factor V2 is ∼14% of
that of factor V1, we conclude that the overall procoagulant
activity of factor V1 under these conditions was 7-fold higher
than that of factor V2.
DISCUSSION
Efficient inactivation of factor Va by APC and protein S
requires the presence of negatively charged membranes
(Walkeret al., 1979; Bakkeret al., 1992). The membrane
presumably acts as a collecting device that binds factor Va,
APC, and protein S and that promotes the assembly of an
anticoagulant complex, thus accelerating factor Va inactiva-
tion by APC. In this paper, we show that one of the plasma
forms of factor Va (i.e., factor Va1) is inactivated by APC
at considerably lower rates than the other form of factor Va
(factor Va2). Factor Va1 and factor Va2 have different light-
chain domains (Rosinget al., 1993; Ortelet al., 1994a,b)
and bind with different affinities to negatively charged
membranes (Rosinget al., 1993). In agreement with this
phenomenon, we observed that differences in the rates of
APC-catalyzed inactivation of factors Va1 and Va2 are
especially observed at low membrane concentrations and on
membranes that contain less than 15 mol % of the anionic
phospholipid phosphatidylserine. At high phospholipid and
phosphatidylserine concentrations, factor Va1 and factor Va2
were inactivated at similar rates. Under these conditions,
the number of available binding sites for factor Va on the
membrane likely exceeds the dissociation constants of the
factor Va-membrane complex of both factor Va1 nd factor
Va2. This results in a situation in which almost all factor
Va1 and Va2 will be bound to the membrane and hence will
be inactivated by APC at comparable rates.
Similar differences between APC-catalyzed inactivation
of factor Va1 and factor Va2 were observed in the presence
of the APC cofactor protein S. This indicates that, at the
chosen reaction conditions, protein S does not affect the
assembly of the factor Va-APC-membrane complex. Our
data confirm that protein S specifically accelerates APC-
catalyzed factor Va1 and Va2 inactivation by increasing the
rate constant of cleavage at Arg306 (Rosinget al., 1995).
Recently, we reported (Nicolaeset al., 1995; Rosinget
al., 1995) a kinetic analysis of APC-catalyzed inactivation
of a factor Va preparation that contained both factor Va1
and factor Va2. Careful assessment of cofactor activity in
prothrombin activation showed that this preparation contained
∼10% factor Va1. Since the experiments reported in these
papers were performed on 25µM PS/PC (10/90, mol/mol)
vesicles, factor Va1 negligibly contributed to factor Va
inactivation, and the given rate constants were actually those
for factor Va2.
Factor Va1 and factor Va2 also exhibited different cofactor
activities in prothrombin activation. However, full expres-
sion of factor Va cofactor activity required much less
phospholipid and phosphatidylserine than APC-catalyzed
factor Va inactivation. This results in a situation in which
at intermediate phospholipid conditions (e.g., 20µM phos-
pholipid with 10 mol % phosphatidylserine) both forms of
factor Va have the same cofactor activity in prothrombin
activation but are inactivated by APC at considerably
different rates (see also below).
When the properties of factor Va1 and factor Va2 are
compared, it appears that their functional difference dimin-
FIGURE4: Effect of the phospholipid composition and concentration
on the cofactor activity of factor Va1 and factor Va2 in prothrombin
activation. 1.5 nM purified human factor Va1 (9) or factor Va2
(b) was incubated at 37°C with 2.5 pM factor Xa in 25 mM Hepes
(pH 7.5), 175 mM NaCl, 3 mM CaCl2, 5 mg/mL BSA, and (A) 5
µM DOPS/DOPC vesicles with varying mole percentages of
phosphatidylserine (DOPS) or (B) varying amounts of DOPS/DOPC
(5/95, mol/mol) vesicles. After 5 min, prothrombin was added to a
final concentration of 1µM. The rate of prothrombin activation
was determined as described under Experimental Procedures.
Plotted are the rate of prothrombin activation as a function of the
phosphatidylserine content of the membranes (A) or as a function
of the phospholipid concentration (B).
FIGURE 5: Comparison of procoagulant activities of factor V1 and
factor V2 in a reaction system containing prothrombinase compo-
nents, APC, and protein S. 1.5 nM purified human factor V1 (9)
or factor V2 (b) was incubated at 37°C with 0.1 nM thrombin, 4
pM factor Xa, 1µM prothrombin, 2 nM APC, 200 nM protein S,
and 12.5µM vesicles containing 10% brain PS, 39% brain PC,
27% brain PE, 19% brain sphingomyelin, and 5% liver PI on a
molar basis in 25 mM Hepes (pH 7.5), 127 mM NaCl, 3 mM CaCl2,
and 5 mg/mL BSA. The amounts of thrombin formed at the
indicated time points were determined as described under Experi-
mental Procedures.
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ishes in the following order: binding affinity for negatively
charged membranes (Rosinget al., 1993), sensitivity for APC
(this paper), and cofactor activity in prothrombin activation
(Rosinget al., 1993; this paper). This can be explained by
the fact (1) that binding experiments yield true affinity
differences of factor Va1 and factor Va2 for membranes
independent of the phospholipid concentration, (2) that in
APC-catalyzed factor Va inactivation this difference may be
(partially) compensated at higher phospholipid concentrations
(binding sitesgKd), and (3) that in prothrombinase measure-
ments the presence of factor Xa (Rosinget al., 1980;
Nesheimet al., 1980; Lindhoutet al., 1982) and prothrombin
(Billy et al., 1996) additionally contributes to the binding
of factor Va to the membrane.
Our observation that much less phospholipid and phos-
phatidylserine are required for full expression of cofactor
activity of factor Va in prothrombin activation than for
regulation of factor Va cofactor activity by APC may have
physiological implications. On membranes with 5-10 mol
% phosphatidylserine, which likely simulate thein ViVo
situation (Beverset al., 1983), factor Va1 and factor Va2 have
similar cofactor activities in prothrombin activation but
exhibit considerable differences in their sensitivity for APC.
This means that, in contrast to the expectation, the overall
procoagulant activity of factor V1 will exceed that of factor
V2 in reaction systems containing membranes with physi-
ologic phospholipid compositions, factor V, factor Xa,
prothrombin, APC, protein S, and traces of thrombin to
initiate factor Va formation. The experiment presented in
Figure 5, which was performed on membranes with the
phospholipid composition of activated platelets, shows that
this is indeed the case. The total amount of thrombin formed
in the reaction system in which factor V was activated by
factor Xa and thrombin and in which the factor Va formed
was simultaneously allowed to express cofactor activity in
prothrombin activation and to be down-regulated by APC
and protein S was 7-fold higher with factor V1 than with
factor V2. This shows that, due to differences in sensitivity
for APC, the overall procoagulant activity of the form of
factor V that has the lowest affinity for membranes (factor
V1) was at least 7 times higher than that of the form of factor
V which has the highest membrane affinity (factor V2).
In a recent paper, Zo¨ller et al. (1994) reported that in
approximately 5% of the APC-resistant families the Arg506-
Gln mutation (factor VLeiden), that is usually associated with
APC resistance (Dahlba¨ck et al., 1993; Bertinaet al., 1994),
is not found and suggested that apart from this mutation
other, as yet unknown, genetic defects may also cause
inherited APC resistance. In addition, Zo¨ller et al. (1994)
decribed that heterozygous carriers of the factor VLeiden
mutation with a history of thrombosis had lower APC
sensitivity ratios than heterozygous family members without
thrombosis. It is conceivable, that individuals with low APC
sensitivities in APTT-based assays may have ratios of
circulating factor V1 and factor V2 that differ from that of
normal individuals (normal plasma contains∼30% factor
V1; Rosinget al., 1993). Based on the observations reported
in the present paper, we are currently developing a method
to quantitate the amounts of factor V1 and factor V2 in
plasma. With such a procedure, we will investigate whether
there is a relation between non-factor VLeiden related APC
resistance, plasma levels of factor V1 and V2, and a possible
risk for venous thrombosis.
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